Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Sign Up to like & getrecommendations! Published in 2021 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab724.2284
Abstract: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and SGLT2 inhibitors have demonstrated clinical benefits in HFrEF and CKD patients with T2D. Cardiovascular protection with finerenone and the SGLT2 inhibitor empagliflozin in combination in hypertensive cardiorenal… read more here.
Keywords: combination; cardiovascular protection; finerenone sglt2; finerenone ... See more keywords